Published in Lab Law Weekly, November 26th, 2004
Third-quarter 2004 gross margin was 54.1% compared with 53.7% in the same quarter last year.
In the 2004 third quarter, the company incurred Abraxane expenses totaling $10.1 million, or $0.09 per diluted share after applicable income taxes. Additionally, the company obtained a $100 million unsecured credit facility in September 2004.
The new credit facility replaced a prior $50 million, 5-year, secured credit facility entered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.